This is the title of a paper published today future oncology With co-authors Erin Mulvey, Ki-Sin Thanh, Sanjana Muthukrishnan, Alex Mutebi, Anindit Chhibber, Anthony Wang, Abulbishar Alsharif, Dialla Harb, Victor Gonzalez, Sarah Quinlan, Vardhaman Patel, and Patrick Connor Johnson. This study was conducted in collaboration with the Lymphoma Research Foundation. The gist is below:
background: Two recently approved specific antibodies (BSAbs) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) include apicoritamab (subcutaneous, SC) administered until progression (TTP), and glofitamab (intravenous, IV) for a fixed period of time (FTD). Understanding patient preferences for treat- mental characteristics is important for making patient-centered decisions.
methods: A separate experiment among 123 DLBCL patients assessed preferences for BsAbs in six characteristics: median overall survival (OS, 12- vs. 18 months), 24-month complete response (CR) (55% vs. 62%), grade 3-4 cytokine release syndrome risk (CRS, 2% vs. 5%), CRS-related hospitalization (2% vs. 56%), duration (FTD vs TTP) and administration (SC vs IV). Preference weights were estimated using conditional logistic regression.
Result: CRS and CRS-related hospitalization were the strongest drivers of preference (1.83, P < 0.001), followed by OS (1.14, P < 0.001), CR (1.13, P < 0.001), duration (0.48, P < 0.001), and administration (0.02, P = 0.877). Patients preferred FTD, but preferred TTP if it reduced CRS (79.3%) or improved survival (65.8%). Patients indicated the importance of efficacy characteristics (OS, 86.2%; CR, 85.4%) and quality of life (QoL, 71.5%) in decision making.
conclusion: Efficacy and safety were the most important factors along with QoL. Patients favored FTD but were willing to compromise for TTP with increased efficacy or safety. These findings can guide physician/patient discussions in therapy selection.
You can read the full paper here.
